FDA Draft Guidance Imminent Following ODAC’s Consideration of Real-World Data in Pediatric Oncology – Targeted Oncology
CONTEXT: As promised, we will keep you up to date on the FDA guidance on RWE in pediatric oncology. It seems the guidance will be available soon, but following a Continue Reading